Abstract
Advanced glycation end products (AGEs) in diabetic nephropathy have been extensively researched over the last decade and are now firmly established as major players in this disease. The enigma remains the search for the ideal AGE inhibition therapy, which is a great challenge in the context of the structural diversity inherent to AGE chemistry. Certainly, there is a requirement to standardize measurements of circulating and tissue levels of AGEs and to characterize the pathogenic potential of specific AGE moieties. In order to develop more effective, targeted approaches to combat diabetic nephropathy, the mechanisms of action of selective AGE inhibitors and the inter-relationships of advanced glycation with other pathogenic pathways must be addressed.
Keywords: advanced glycation end products, diabetes, diabetic nephropathy, age inhibitor, cross-link breaker, cml, pentosidine, rage
Current Pharmaceutical Design
Title: Advanced Glycation: How are we Progressing to Combat this Web of Sugar Anomalies in Diabetic Nephropathy
Volume: 10 Issue: 27
Author(s): Josephine M. Forbes, Vicki Thallas-Bonke, Mark E. Cooper and Merlin C. Thomas
Affiliation:
Keywords: advanced glycation end products, diabetes, diabetic nephropathy, age inhibitor, cross-link breaker, cml, pentosidine, rage
Abstract: Advanced glycation end products (AGEs) in diabetic nephropathy have been extensively researched over the last decade and are now firmly established as major players in this disease. The enigma remains the search for the ideal AGE inhibition therapy, which is a great challenge in the context of the structural diversity inherent to AGE chemistry. Certainly, there is a requirement to standardize measurements of circulating and tissue levels of AGEs and to characterize the pathogenic potential of specific AGE moieties. In order to develop more effective, targeted approaches to combat diabetic nephropathy, the mechanisms of action of selective AGE inhibitors and the inter-relationships of advanced glycation with other pathogenic pathways must be addressed.
Export Options
About this article
Cite this article as:
Forbes M. Josephine, Thallas-Bonke Vicki, Cooper E. Mark and Thomas C. Merlin, Advanced Glycation: How are we Progressing to Combat this Web of Sugar Anomalies in Diabetic Nephropathy, Current Pharmaceutical Design 2004; 10 (27) . https://dx.doi.org/10.2174/1381612043383151
DOI https://dx.doi.org/10.2174/1381612043383151 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current Challenges to Overcome in the Management of Type 2 Diabetes Mellitus and Associated Neurological Disorders
CNS & Neurological Disorders - Drug Targets A Molecular Approach on the Protective Effects of Mangiferin Against Diabetes and Diabetes-related Complications
Current Diabetes Reviews Oxidative stress and myocarditis
Current Pharmaceutical Design Propitious Profile of Peppery Piperine
Current Molecular Pharmacology Antioxidants in the Treatment of Diabetes
Current Diabetes Reviews Asymmetric Dimethylarginine (ADMA): A Promising Biomarker for Cardiovascular Disease?
Current Topics in Medicinal Chemistry A Review on Rheumatoid Arthritis Interventions and Current Developments
Current Drug Targets The Anti-Inflammatory Potential of ACE2/Angiotensin-(1-7)/Mas Receptor Axis: Evidence from Basic and Clinical Research
Current Drug Targets Clinical Evidence of Herb-Drug Interactions: A Systematic Review by the Natural Standard Research Collaboration
Current Drug Metabolism Human Recombinant Leptin Administration as a Potential Obesity Therapy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Prevention of Renal Complications Induced by Non- Steroidal Anti-Inflammatory Drugs
Current Medicinal Chemistry The Quest for Novel Biomarkers in Early Diagnosis of Diabetic Neuropathy
Current Proteomics Interindividual Variability in the Efficacy of Oral Antiplatelet Drugs: Definitions, Mechanisms and Clinical Importance
Current Pharmaceutical Design An Overview on Diabetic Foot Infections, including Issues Related to Associated Pain, Hyperglycemia and Limb Ischemia
Current Pharmaceutical Design Acute Renal Failure in Different Malignant Tumors
Current Medicinal Chemistry Targeting the NLRP3 Inflammasome in Diabetic Nephropathy
Current Medicinal Chemistry Rational Targeting of Peroxisome Proliferating Activated Receptor Subtypes
Current Medicinal Chemistry Urotensin II: A Vascular Mediator in Health and Disease
Current Vascular Pharmacology Subclinical Hypothyroidism in Patients with Diabetic Retinopathy: Role of Vascular Endothelial Growth Factor
Endocrine, Metabolic & Immune Disorders - Drug Targets Ethnicity Considerations in Diagnosing Glucose Disorders
Current Diabetes Reviews